Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2025 |
|---|---|
| Revenue | $44.6M |
| R&D expense | $250,000 |
| Operating income | −$6.3M |
| Net income | −$9.7M |
| Cash & equivalents | $36.8M |
| Total debt | — |
| Operating cash flow | −$12.5M |
| Free cash flow | −$12.5M |
Company profile
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.